Member Info for technick

Genedrive developed software to allow all instruments to analyse the data

db says he doesn't see any real why this wouldn't translate into significant sales revenue for the company?

global market of £40-£65m per year

revolutionary approach to doing genetic screening in children

to develop a genetic test for hearing loss due to antibiotic uses in infants, first on the world to offer POC solution

look forward to reporting sales in the very near future

we have every right to be excited about our product

..

users reporting positive feedback

fewest number of steps from sample to answer for any test thats available in market

great data, great sensitivity, can pick up low level infectivity, really is a gold standard performance.

no one else has managed to produce a freeze dried all in one reagent bead thats room temperature stable and just add sample

... 10k tests per hour manufacture capability, £8-£10 and 60% gross margin

no, that's new. it makes the test much easier to do, really very nice

from saliva!

wow, point of care SARS test in 30 minutes at POC!!

that is interesting, and the link to the chart is here..

https://ourworldindata.org/epi-curve-covid-19

shows that the countries doing more tests per day have a quicker drop in numbers... go figure

https://www.theguardian.com/world/live/2020/jun/11/coronavirus-live-news-us-cases-near-2-million-as-mexico-city-ramps-up-testing-in-push-to-reopen

a lot of late reported trades every day, so definitely games. and a lack of TR1's considering £8m of new shares. Hoping after tomorrow we can resume normal service

I suspect that we can't actually see from the major shareholders where the £8m is, so I suspect Peel have been placing most of it straight into the market since the placing which although it has suppressed the share price, it does show demand for the share. Now we are at the 11th we may see TR1s and we may see more of a retail effect on share price upwards... guessing